These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 31655622

  • 1. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
    Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E.
    Arthritis Res Ther; 2019 Oct 26; 21(1):217. PubMed ID: 31655622
    [Abstract] [Full Text] [Related]

  • 2. Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.
    Xanthouli P, Uesbeck P, Lorenz HM, Blank N, Eichstaedt CA, Harutyunova S, Egenlauf B, Coghlan JG, Denton CP, Grünig E, Benjamin N.
    Arthritis Res Ther; 2024 Jul 18; 26(1):136. PubMed ID: 39026360
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y, Jing ZC, Zeng XF, Liu JM, Yu ZX, Zhang GC, Li Y, Wang Y, Ji QS, Zhu P, Wu BX, Zheng Y, Wang PP, Li J.
    BMC Cardiovasc Disord; 2016 Oct 22; 16(1):201. PubMed ID: 27770771
    [Abstract] [Full Text] [Related]

  • 4. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group.
    Circulation; 2008 Jun 10; 117(23):3010-9. PubMed ID: 18506008
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S, Pollock DM, Gillies H, Henig N, Allard M, Blair C, Anglen C, Kohan DE.
    Am J Cardiol; 2012 Nov 01; 110(9):1373-7. PubMed ID: 22858181
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.
    Lancet Respir Med; 2016 Nov 01; 4(11):894-901. PubMed ID: 27745818
    [Abstract] [Full Text] [Related]

  • 12. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.
    Am J Cardiol; 2011 Jul 15; 108(2):302-7. PubMed ID: 21545989
    [Abstract] [Full Text] [Related]

  • 13. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G, Mehta S.
    Appl Health Econ Health Policy; 2009 Jul 15; 7(1):43-59. PubMed ID: 19558194
    [Abstract] [Full Text] [Related]

  • 14. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG.
    Ann Rheum Dis; 2020 May 15; 79(5):626-634. PubMed ID: 32161055
    [Abstract] [Full Text] [Related]

  • 15. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS.
    J Heart Lung Transplant; 2020 May 15; 39(5):464-472. PubMed ID: 32008947
    [Abstract] [Full Text] [Related]

  • 16. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ, ARIES Study Group.
    J Am Coll Cardiol; 2009 Nov 17; 54(21):1971-81. PubMed ID: 19909879
    [Abstract] [Full Text] [Related]

  • 17. Sildenafil Versus Placebo for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS): protocol for a randomized controlled trial.
    Lammi MR, Mukherjee M, Saketkoo LA, Carey K, Hummers L, Hsu S, Krishnan A, Sandi M, Shah AA, Zimmerman SL, Hassoun PM, Mathai SC.
    BMC Pulm Med; 2024 Apr 30; 24(1):211. PubMed ID: 38689245
    [Abstract] [Full Text] [Related]

  • 18. [Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].
    Volkov AV, Kurmukov IA, Yudkina NN, Glukhova SI, Nikolaeva EV.
    Ter Arkh; 2015 Apr 30; 87(1):49-56. PubMed ID: 25823269
    [Abstract] [Full Text] [Related]

  • 19. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):529-35. PubMed ID: 16053970
    [Abstract] [Full Text] [Related]

  • 20. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ, AMBITION investigators.
    Ann Rheum Dis; 2017 Jul 02; 76(7):1219-1227. PubMed ID: 28039187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.